S-1: Envoy Medical Registers 15.1M Shares for Resale

Envoy Medical, a hearing health company, filed an S-1 registration statement for the resale of over 15 million shares by selling stockholders, while advancing its Acclaim cochlear implant clinical trials and addressing Nasdaq listing compliance.

Summary

• Filed an S-1 registration statement for the resale of up to 15,116,472 shares of Class A Common Stock by selling stockholders.
• The company will not receive proceeds from the sale of these shares, but could receive approximately $20.1 million if all associated warrants are exercised for cash.
• Acclaim CI pivotal clinical trial advanced to Stage 2 after successful Stage 1 (10 patients completed 3-month follow-up with no serious adverse events). Stage 2 will enroll an additional 46 patients, totaling 56.
• Anticipates FDA decision on Premarket Approval (PMA) for Acclaim CI in the second half of 2027 or first half of 2028.
• Reported net losses of $5.7 million for the three months ended June 30, 2025, and $10.7 million for the six months ended June 30, 2025.
• Accumulated deficit reached $297.9 million as of June 30, 2025.
• Received a Nasdaq notice of non-compliance with minimum stockholders' equity requirement on March 25, 2025, and a determination letter on August 26, 2025, for not regaining compliance with the Market Value of Listed Securities (MVLS) requirement. A hearing request was submitted by September 2, 2025.
• Secured $30.0 million in term loans from a related party (GAT Funding, LLC) between February 2024 and June 2025, which were fully satisfied for a one-time payment of $100,000 on August 25, 2025.

Sentiment

Score: 3

Explanation: Envoy Medical faces significant financial distress, including substantial net losses, an accumulated deficit, and a "going concern" warning. Its Nasdaq listing is under threat due to non-compliance with equity and market value requirements. While the Acclaim CI clinical trial is advancing, and a large related-party debt was settled for a nominal amount, the company continues to rely heavily on external funding, and its stock price is significantly underperforming. The identified design flaw in the Acclaim CI's early feasibility study adds uncertainty to its future commercial success.

Positives

• Acclaim CI pivotal clinical trial successfully advanced to Stage 2, with all 10 Stage 1 patients completing 3-month follow-up without serious adverse events.
• Preliminary clinical data for Acclaim CI effectively characterized its potential effectiveness for its intended use.
• The Acclaim CI has Breakthrough Device Designation from the FDA, which may expedite development and review.
• The fully implanted nature of Acclaim CI offers potential competitive advantages over existing cochlear implants, including increased daily usage, hearing at night and in water, and reduced stigma.
• The cochlear implant market has established acceptance and reimbursement pathways, unlike the company's previous product.
• A new bipartisan Congressional bill (Hearing Device Coverage Clarification Act, Feb 2024) could reclassify the Esteem FI-AMEI as a prosthetic, potentially enabling Medicare/Medicaid coverage and commercial viability.
• Significant debt ($30.0 million in Term Loans) from a related party was fully satisfied for a one-time payment of $100,000, significantly reducing liabilities.
• The company has a strong intellectual property portfolio with 37 issued U.S. patents and 38 issued foreign patents.

Negatives

• The company reported continued significant net losses ($5.7 million for Q2 2025, $10.7 million for 6 months ended June 30, 2025) and an accumulated deficit of $297.9 million, indicating ongoing financial challenges.
• Received a "going concern" warning, highlighting substantial doubt about its ability to continue operations.
• Non-compliance with Nasdaq's minimum stockholders' equity and Market Value of Listed Securities (MVLS) requirements, leading to a potential delisting.
• The company will not receive any direct proceeds from the current resale offering of 15.1 million shares by selling stockholders.
• The Early Feasibility Study (EFS) for Acclaim CI identified a signal-to-noise issue (gurgling/sizzling background noise) requiring mitigation.
• Two of three EFS patients use a hearing aid in conjunction with the Acclaim CI to mitigate the noise issue, suggesting the device may not fully meet its "fully implanted" promise without external assistance in its current form.
• The Esteem FI-AMEI, despite FDA approval in 2010, failed to gain commercial traction due to lack of reimbursement, highlighting past commercialization challenges.
• The company expects to continue incurring significant net losses and increasing expenses for the foreseeable future, particularly for R&D, sales, and marketing for Acclaim CI.
• The market price of Class A Common Stock ($0.92 on Oct 14, 2025) is significantly below the exercise price of Public Warrants ($11.50), making their exercise unlikely and indicating poor market performance.
• The company's management team has limited experience managing a public company, which could strain resources and divert attention.

Risks

• The market price of Class A Common Stock has been and may continue to be extremely volatile, which could cause purchasers of securities to incur substantial losses.
• Failure to meet Nasdaq's continued listing requirements could result in a delisting of Class A Common Stock from Nasdaq, negatively affecting price and liquidity.
• The company is an early-stage company with a history of losses and may not be able to achieve profitability in the future, raising substantial doubt about its ability to continue as a going concern.
• The company expects to need to raise substantial additional funding, which may not be available on acceptable terms, or at all, potentially requiring curtailment or discontinuation of product development.
• Future equity offerings would cause dilution to existing stockholders and may adversely affect their rights.
• Clinical failure can occur at any stage of clinical development, and the Acclaim CI may not have favorable results in later clinical trials or receive regulatory approval.
• If the Acclaim CI contains design or manufacturing defects, the business and financial results could be harmed, as evidenced by the signal-to-noise issue in the Early Feasibility Study.
• The successful commercialization of the Acclaim CI, if it receives FDA approval, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels, and favorable pricing policies.
• The company operates in a very competitive business environment with larger, more established competitors, and inability to compete successfully could adversely affect the business.
• The company expects to derive most of its revenues from sales of the Acclaim CI, and inability to successfully commercialize this product candidate could severely harm revenue generation.
• If healthcare professionals do not recommend the product to their patients, the Acclaim CI may not achieve market acceptance and the company may not become profitable.
• The company will be dependent upon contract manufacturing organizations and material suppliers, making it vulnerable to supply shortages, increased costs, and quality or compliance issues.
• The size and expected growth of the addressable market for the product has not been established with precision and may be smaller than estimated.
• The company will depend on third parties to manage preclinical studies and clinical trials, perform related data collection and analysis, and to enroll patients, which may lead to costs and delays beyond its control.
• The company has been and may in the future become a defendant in one or more stockholder derivative, class-action, and other litigation, which may adversely affect the business and divert management attention.
• The company is highly dependent on key members of its executive management team, and inability to retain these individuals could impede business plans and growth strategies.
• If the company is unable to obtain significant patent protection for its products, or if patents and other intellectual property rights do not adequately protect products, it may be unable to gain significant market share.
• Failure of a key information technology system, process, or site could have an adverse effect on the business, including from cyberattacks.
• Unfavorable global economic conditions, including inflation and interest rate increases, could adversely affect the business, financial condition, or results of operations.
• The company has identified material weaknesses in its internal control over financial reporting, which, if not remediated, could adversely affect investor confidence and the value of common stock.
• The market price of Class A Common Stock may decrease due to resales by current stockholders concerned about potential ownership dilution from new share issuances.

Future Outlook

The company anticipates obtaining FDA approval for its Acclaim CI in the second half of 2027 or first half of 2028, which is crucial for generating product sales. It expects to continue incurring significant net losses and increasing expenses for the foreseeable future as it advances clinical trials, seeks regulatory approvals, and prepares for commercialization. The commercialization strategy involves a phased rollout to carefully selected surgical sites, with significant investments planned for infrastructure, sales, distribution, and training post-FDA approval. The company also plans to pursue CE Mark approval in the European Union after FDA approval and explore other international markets. Research and development will focus on improving the Acclaim CI design, quality, reliability, and software, potentially expanding the cochlear electrode array portfolio.

Management Comments

• Our vision is to create fully implanted hearing devices that leverage the natural ear not an artificial microphone to pick up sound.
• We believe that the Acclaim CI is a first-of-its-kind cochlear implant.
• We believe that Acclaim CI gives us the opportunity to disrupt the existing cochlear implant market.
• We currently anticipate obtaining the FDA's decision on our PMA at some point within the second half of 2027 or first half of 2028, depending on the FDA's review process and timeline.
• The FDA approval process is uncertain and there can be no guarantees of whether the Acclaim CI will ever successfully receive FDA approval.
• We expect to continue to incur net losses for the foreseeable future, and expect our research and development expenses, sales and marketing expenses, general and administrative expenses, and capital expenditures will continue to increase.
• We believe we demonstrated to the Panel several different viable and relatively near-term pathways to regain compliance [with Nasdaq listing requirements].
• We believe hearing aid classification is improper for the Esteem FI-AMEI and we continue to work towards having the Esteem FI-AMEI properly classified as a Fully Implanted Active Middle Ear Implant.
• We believe that the fully implanted nature of the Acclaim CI will facilitate an increase in daily usage over other types of cochlear implants because the device can be used 24-hours a day.
• We believe we can increase penetration rates for adult cochlear implants in the U.S.
• We believe that if we are able to establish distribution channels and strategic relationships with clinics and healthcare professionals the Acclaim CI will be in a unique position to capture existing market share quickly and to also capture a healthy portion of the unserved market.
• It is reasonable to believe that Acclaim CI will demand a higher average selling price than existing partially implanted cochlear implants.
• We believe physicians and patients will be receptive to its competitive advantage as a fully implanted cochlear implant.
• We believe strong relationships can be built with both surgical teams and audiologists to ensure both are able to understand the options and benefits of the technology and differentiate themselves from the marketplace by offering and working with the Acclaim CI.
• We view pursuing the commercialization of the Acclaim CI as the appropriate focus and best use of resources.
• We believe that our existing facility is sufficient to meet our needs for the foreseeable future.
• We consider our relationship with our employees to be good.
• The Company believes that the lawsuit [by Atlas Merchant Capital] is meritless and has been defending this matter vigorously.
• Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued.

Industry Context

The company operates in the hearing health industry, specifically targeting the cochlear implant market, which is dominated by a few major players like Cochlear Ltd. (60% global market share), Advanced Bionics (Sonova), and Med-El. The industry has seen trends towards improved appearance, usability, connectivity, lifestyle integration, and miniaturization of devices, as well as loosening clinical candidacy requirements (e.g., expanded Medicare/Medicaid coverage, single-sided deafness treatment). Envoy Medical aims to disrupt this market with its fully implanted Acclaim CI, which leverages natural ear anatomy for sound capture, offering advantages over partially implanted devices. The company's previous product, Esteem FI-AMEI, failed due to lack of reimbursement, highlighting the critical role of coverage pathways in this industry. The potential reclassification of FI-AMEIs as prosthetics could significantly alter the market for such devices.

Comparison to Industry Standards

• Market Penetration: Industry sources and the company's market research estimate a 5-8% penetration rate for cochlear implants in the adult population, indicating a large untapped market. The company believes its Acclaim CI can capture existing and unserved market share.
• Competitive Landscape: The cochlear implant market is dominated by a few large, diversified medical device companies (Cochlear Ltd., Advanced Bionics, Med-El) with substantially greater sales, financial resources, established distribution networks, and relationships with healthcare professionals. Envoy Medical is a smaller, early-stage company with limited market history.
• Reimbursement: Unlike the Esteem FI-AMEI, which was improperly classified as a hearing aid and lacked reimbursement, the Acclaim CI is expected to be eligible for Medicare and Medicaid coverage as a cochlear implant, aligning with established industry reimbursement pathways.
• Technological Innovation: The Acclaim CI is positioned as a "first-of-its-kind" fully implanted cochlear implant leveraging natural ear anatomy, aiming to differentiate from traditional partially implanted devices that use external microphones. This represents a potential shift in hardware design focus within the industry.
• Pricing: The company believes Acclaim CI will demand a higher average selling price than existing partially implanted cochlear implants (assumed $30,000 vs. $25,000 average for traditional CIs), suggesting a premium positioning.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit filed November 14, 2023, by Atlas Merchant Capital SPAC Fund I LP against the Company, former CEO Whitney Haring-Smith, former CFO Daniel Hirsch, and Anzu SPAC GP I LLC in the Delaware Court of Chancery.
• Atlas alleges it was not allowed to redeem its shares of Common Stock and that defendants acted to prevent Atlas's attempt to redeem shares.
• Atlas asserts damages of approximately $9.4 million, plus preand post-judgment interest, costs, and reasonable attorneys' fees.
• The company believes the lawsuit is meritless and is vigorously defending it.
• The company has standard indemnification obligations to Dr. Haring-Smith and Mr. Hirsch.

Related Party Transactions

• Term Loans: GAT Funding, LLC (controlled by Glen A. Taylor, a former director and controlling stockholder) provided $30.0 million in term loans (February 2024, August 2024, March 2025 Term Loans) at 8.0% interest.
• Debt Forgiveness: On August 25, 2025, GAT Funding, LLC agreed to fully satisfy all principal and interest obligations under the Term Loans for a one-time payment of $100,000.
• Voting and Warrant Extension Agreement: On September 4, 2025, GAT Funding, LLC, Taylor Sports Group, Inc. (controlled by Mr. Taylor), and Glen A. Taylor (collectively, the Taylor Parties) agreed to vote in favor of Nasdaq compliance proposals until December 31, 2028. In exchange, the exercise term for Term Loan Warrants was extended to December 31, 2028, and resale of Taylor Parties' Class A Common Stock will be registered.
• Facility Lease: The company leases its headquarters office space in Minnesota from Taylor Corporation, an entity controlled by Glen Taylor. $180,000 was paid under this lease in 2024.
• Shared Services Arrangement: The company has an arrangement with Taylor Technology Services, Inc. (indirectly owned by Glen Taylor) for IT support services, with expenses less than $0.1 million for each of the three and six months ended June 30, 2025 and 2024.
• Sponsor Induced Conversion: On December 20, 2024, Anzu SPAC GP I LLC (the Sponsor) waived $3.7 million in accrued dividends on Series A Preferred Stock and converted 373,333 shares of Series A Preferred Stock into 1,028,986 shares of Common Stock at a temporarily reduced conversion price of $3.63 per share. The company also waived restrictions on 1,000,000 Contingent Sponsor Shares held by the Sponsor.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the exercise of warrants and future capital raises. The current resale offering does not provide direct proceeds to the company. The ongoing Nasdaq delisting threat poses a risk to liquidity and share price. The stock has experienced extreme volatility.
• Employees: Continued investment in R&D and potential commercialization efforts could lead to hiring, but ongoing losses and "going concern" status create uncertainty. Employee stock purchase plan offers benefits.
• Customers (Patients): Potential for a new, innovative fully implanted cochlear implant (Acclaim CI) to address severe to profound hearing loss, offering improved quality of life. However, the product is still investigational, and a signal-to-noise issue was identified in early studies.
• Suppliers: Reliance on third-party suppliers for critical components makes the company vulnerable to supply shortages and increased costs.
• Creditors: The company has significant debt, though a large related-party loan was recently satisfied for a nominal amount. The "going concern" warning indicates financial risk.
• Regulatory Bodies: The company is subject to extensive FDA and other regulatory oversight for medical device development and commercialization.

Next Steps

• Begin the second stage of the Acclaim CI pivotal clinical trial with an additional 46 patients in the coming weeks.
• Collect and analyze data after all 56 patients complete their 12-month follow-up visits.
• Submit a Premarket Approval (PMA) application to the FDA upon finalization of clinical study results.
• Address the signal-to-noise issue identified in the Acclaim CI Early Feasibility Study.
• Continue efforts to regain compliance with Nasdaq listing requirements, following the hearing request submitted to the Hearings Panel.
• Seek additional regulatory and marketing approvals for Acclaim CI in jurisdictions outside the United States, starting with the CE Mark in the European Union after FDA approval.
• Establish a sales, marketing, and distribution infrastructure to commercialize Acclaim CI, if regulatory approval is obtained.
• Identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of the current product candidate.
• Maintain, protect, and expand the intellectual property portfolio.
• Identify, hire, and retain additional skilled personnel.
• Create additional infrastructure to support operations as a public company and commercialization efforts.
• Continue working towards reclassifying the Esteem FI-AMEI as a prosthetic to enable Medicare/Medicaid coverage.
• Evaluate capital requirements and seek additional funding through equity offerings, debt financings, or other arrangements as needed.

Key Dates

Recommendation

Envoy Medical is at a critical juncture. While the advancement of the Acclaim CI to Stage 2 clinical trials and the significant debt forgiveness are positive developments, the company faces severe financial challenges, including persistent net losses, a "going concern" warning, and the imminent threat of Nasdaq delisting. The current S-1 filing is for resale by existing stockholders, meaning no direct capital infusion from this offering. The identified signal-to-noise issue in the Acclaim CI's early study adds uncertainty to its commercial timeline and success. Given the high risks associated with its financial stability, regulatory hurdles, and product development, a "buy" recommendation is premature. However, the potential for a disruptive fully implanted cochlear implant and the recent debt restructuring offer some long-term upside if the company can navigate its immediate challenges. Therefore, a "hold" is appropriate for investors who already own shares and are willing to tolerate high risk, awaiting clearer signs of financial stability and successful commercialization. New investors should exercise extreme caution.

Keywords

Envoy Medical, COCH, Cochlear Implant, Acclaim CI, Hearing Health, Medical Device, FDA Approval, Clinical Trials, Nasdaq Listing, Capital Raise, Warrants, Dilution, Going Concern, Intellectual Property, Related Party Transactions, Biotech, Healthcare Technology, S-1 Filing